SC 13G: Kiniksa Pharmaceuticals International, plc
Ticker: KNSA · Form: SC 13G · Filed: 2024-11-08T00:00:00.000Z
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by Kiniksa Pharmaceuticals International, plc.
Risk Assessment
Risk Level: low
From the Filing
EDGAR Filing Documents for 0002012383-24-004025 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home Company Search Current Page Form SC 13G - Statement of Beneficial Ownership by Certain Investors: SEC Accession No. 0002012383-24-004025 Filing Date 2024-11-08 Accepted 2024-11-08 17:31:18 Documents 1 Document Format Files Seq Description Document Type Size 1 gb00brxb0c07_110824.txt SC 13G 12218 Complete submission text file 0002012383-24-004025.txt 14053 Mailing Address 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ Business Address 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ 7814319100 Kiniksa Pharmaceuticals International, plc (Subject) CIK : 0001730430 (see all company filings) EIN. : 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231 Type: SC 13G | Act: 34 | File No.: 005-90491 | Film No.: 241442061 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences) Mailing Address 50 HUDSON YARDS NEW YORK NY 10001 Business Address 50 HUDSON YARDS NEW YORK NY 10001 (212) 810-5300 BlackRock, Inc. (Filed by) CIK : 0002012383 (see all company filings) EIN. : 991116001 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G SIC : 6211 Security Brokers, Dealers & Flotation Companies (CF Office: 02 Finance)